Home › Funds › Bellevue Group AG › CGON
Bellevue Group AG position in CGON
CG ONCOLOGY INC · Health Care
Bellevue Group AG reported holding 493,596 shares of CGON (CG ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$35.1M, representing 0.74% of its reported portfolio and ranking #37 among its reported holdings. Bellevue Group AG has disclosed CGON holdings in 2 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's CGON position evolved
Bellevue Group AG first disclosed a stake in CGON in Q4 2025 at 3,095 shares (US$129K). The position peaked in Q2 2026 at 493,596 shares, worth US$35.1M. Across 2 filings, Bellevue Group AG held the position steady without any share-count change. The most recent filing (Q2 2026) shows 493,596 shares valued at US$35.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 3.10K | $128.50K | New |
| Q2 2026 | 493.60K | $35.07M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGON and 13F data
CGON (CG ONCOLOGY INC) is a Health Care company. 52 other funds we track also report a position in CGON — the largest reported positions include RTW INVESTMENTS, LP (US$605.0M), Decheng Capital LLC (US$452.7M), TCG Crossover Management, LLC (US$260.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGON
- RTW INVESTMENTS, LP 8.51M sh · $604.96M · Q2 2026
- Decheng Capital LLC 6.37M sh · $452.71M · Q2 2026
- TCG Crossover Management, LLC 3.67M sh · $260.77M · Q2 2026
- Foresite Capital Management VI LLC 2.37M sh · $168.36M · Q2 2026
- Seven Fleet Capital Management LP 1.89M sh · $134.02M · Q2 2026
- DV Trading LLC 1.44M sh · $102.27M · Q2 2026
- Avidity Partners Management LP 1.40M sh · $99.40M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.13M sh · $80.39M · Q2 2026
- Foresite Capital Management V, LLC 1.08M sh · $76.67M · Q2 2026
- Logos Global Management LP 1.00M sh · $71.05M · Q2 2026
- ORBIMED ADVISORS LLC 972.80K sh · $69.12M · Q2 2026
- Jefferies Financial Group Inc. 769.95K sh · $54.70M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held CGON?
Bellevue Group AG has disclosed CGON holdings in 2 of the last 3 reported quarters, going back to Q4 2025.
What is Bellevue Group AG's current position in CGON?
As of Q2 2026, Bellevue Group AG holds 493.60K shares of CGON (CG ONCOLOGY INC), valued at $35.07M, representing 0.74% of its reported portfolio and ranking #37.
Has Bellevue Group AG been buying or selling CGON?
In the latest 13F filing (Q2 2026), Bellevue Group AG newly opened its position in CGON. The position peaked in Q2 2026 at 493.60K shares.
Which other funds hold CGON?
Other major institutional holders of CGON include RTW INVESTMENTS, LP, Decheng Capital LLC, TCG Crossover Management, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.